预约演示
更新于：2025-02-14
Vortioxetine Hydrobromide
氢溴酸伏硫西汀
更新于：2025-02-14
概要
基本信息
药物类型 小分子化药 |
别名 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine monohydrobromide、VORTIOXETINE、Vortioxetine hydrobromide (JAN/USAN) + [16] |
作用机制 5-HT1A receptor激动剂(5-羟色胺1A受体激动剂)、5-HT1B receptor激动剂(5-羟色胺1B受体激动剂)、5-HT1D receptor拮抗剂(5-羟色胺1D受体拮抗剂) |
治疗领域 |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2013-09-30), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C18H23BrN2S |
InChIKeyVNGRUFUIHGGOOM-UHFFFAOYSA-N |
CAS号960203-27-4 |
关联
191
项与 氢溴酸伏硫西汀 相关的临床试验CTRI/2024/09/073258
To assess the safety, effectiveness and utility of vortioxetine as initial line therapy in the Management of depression through an observational, multicenter Study - IMPRESS
NCT06604520
Functional Neuroimaging to Examine Affective Symptoms and Cognition in Frontotemporal Dementia
NCT06805266
An Open Study to Evaluate the Efficacy of Vortioxetine on Freezing of Gait in Patients Affected by Parkinson Disease with Depressive Symptoms
100 项与 氢溴酸伏硫西汀 相关的临床结果
登录后查看更多信息
100 项与 氢溴酸伏硫西汀 相关的转化医学
登录后查看更多信息
100 项与 氢溴酸伏硫西汀 相关的专利（医药）
登录后查看更多信息
1,072
项与 氢溴酸伏硫西汀 相关的文献（医药）2025-05-01Current Neuropharmacology
Disease-Modifying Symptomatic Treatment (DMST): The Potential Role of Vortioxetine in the Treatment of Depression in Patients with Multiple Sclerosis
Article
作者: Totaro, Rocco ; Clerici, Valentina Torri ; Centonze, Diego ; Annovazzi, Pietro ; Marfia, Girolama Alessandra ; Conte, Antonella ; Bruno, Antonio ; Clerico, Marinella ; Cocco, Eleonora ; Tomassini, Valentina ; Salvetti, Marco ; Dolcetti, Ettore
In multiple sclerosis (MS), alongside the physical symptoms, individuals often grapple
with anxiety and depressive symptoms as prevalent comorbidity. Mood disturbances, frequently undertreated
in clinical practice, significantly impact the quality of life of individuals with MS, exacerbating
disability and hindering overall well-being. Furthermore, traditional antidepressant therapies
are often associated with adverse events, such as sexual side effect, weight gain, which could limit
their use in these patients. Vortioxetine is one of the most innovative antidepressant drugs in the current
pharmacopeia. Its pharmacological profile includes serotonin reuptake inhibition, antagonism
for hydroxytryptamine (HT) receptors 5-HT3, 5-HT1D and 5-HT7, partial agonism for 5-HT1B, and
agonism for 5-HT1A. It has been shown to have a beneficial effect on depression-related cognitive
dysfunction, as well as on anxiety, depression, anhedonia and emotional blunting. Recently a potential
anti-inflammatory action was also described. Limited clinical studies have specifically explored
the efficacy of vortioxetine in treating depressive symptoms in MS. However, extrapolating from existing
research in major depressive disorder, it is plausible that vortioxetine's multimodal mechanism
could provide a favorable therapeutic approach. This position paper, which summarizes the output of
annual clinical meeting held by the DMSTs in MS Italian Study Group, is focused on the possible
role that vortioxetine could play as symptomatic treatment (ST) of depressed patients with MS, hypothesizing
a direct impact on the clinical course of the disease.
2025-03-01AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
A Systematic Review of Antidepressants and Psychotherapy Commonly Used in the Treatment of Late Life Depression for Their Effects on Cognition
Article
作者: Gandelman, Jason A ; Gandelman, Jason A. ; Nelson, J Craig ; Gandelman, Jason ; Mackin, R Scott ; Nelson, J. Craig ; Mackin, R. Scott
Cognitive dysfunction is common in late life depression (LLD) and is a major risk factor for dementia. Recent studies show limited improvement in cognition with commonly employed treatments for LLD, contradicting the notion that cognition "returns to normal" with treatment. However, findings differ with the treatments used. The aim of this study is to perform a systematic review of studies of antidepressants and psychotherapies commonly employed in LLD to determine their effects on cognition, particularly processing speed, memory, and executive function. We searched for trials of acute phase treatment, in nondemented individuals 60 years and older with unipolar nonpsychotic Major Depressive Disorder, that assessed cognitive performance with neuropsychological tests before and after treatment. We compared the magnitude of change in cognition by examining within group effect sizes. Six antidepressant trials and two psychotherapy trials (both using Problem Solving Therapy)(PST) provided relatively comparable data that allowed for quantitative comparison. Nine other antidepressant trials provided descriptive findings. Sertraline and vortioxetine had significant positive effects on processing speed and memory. Duloxetine had significant effects on memory. The most selective SRIs-citalopram and escitalopram-had minimal effects on cognition and citalopram had adverse effects in depression nonresponders. PST had modest effects on processing speed and no effect on memory. Effects of practice and improvement in depression on cognition are examined. In all but one study, cognition was a secondary outcome and various quality indicators (e.g. blinding cognitive assessment to treatment) were often not reported. As a consequence, these findings must be considered preliminary.
2025-03-01Journal of Zhejiang University-SCIENCE B
Clinical efficacy and safety of vortioxetine as an adjuvant drug for patients with bipolar depression
Article
作者: Zhou, Chengcheng ; Fu, Yaoyang ; Dai, Chunxiao ; Li, Xiao ; Li, Xuanwei ; Hu, Shaohua ; Huang, Keke ; Zhao, Qingwei ; Xie, Jian ; Li, Yinbo ; Lin, Meihua
OBJECTIVES:
Whether vortioxetine has a utility as an adjuvant drug in the treatment of bipolar depression remains controversial. This study aimed to validate the efficacy and safety of vortioxetine in bipolar depression.
METHODS:
Patients with bipolar Ⅱ depression were enrolled in this prospective, two-center, randomized, 12-week pilot trial. The main indicator for assessing treatment effectiveness was a Montgomery-Asberg Depression Rating Scale (MADRS) of ≥50%. All eligible patients initially received four weeks of lurasidone monotherapy. Patients who responded well continued to receive this kind of monotherapy. However, no-response patients were randomly assigned to either valproate or vortioxetine treatment for eight weeks. By comprehensively comparing the results of MADRS over a period of 4‒12 weeks, a systematic analysis was conducted to determine whether vortioxetine could be used as an adjuvant drug for treating bipolar depression.
RESULTS:
Thirty-seven patients responded to lurasidone monotherapy, and 60 patients were randomly assigned to the valproate or vortioxetine group for eight weeks. After two weeks of combined valproate or vortioxetine treatment, the MADRS score in the vortioxetine group was significantly lower than that in the valproate group. There was no difference in the MADRS scores between the two groups at 8 and 12 weeks. The incidence of side effects did not significantly differ between the valproate and vortioxetine groups. Importantly, three patients in the vortioxetine group appeared to switch to mania or hypomania.
CONCLUSIONS:
This study suggested that lurasidone combination with vortioxetine might have potential benefits to bipolar II depression in the early stage, while disease progression should be monitored closely for the risk of switching to mania.
100 项与 氢溴酸伏硫西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 中国 | 2017-11-21 | |
| 重度抑郁症 | 美国 | 2013-09-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 创伤性脑损伤 | 临床3期 | - | 2016-10-01 | |
| 认知功能障碍 | 临床3期 | - | 2011-12-01 | |
| 中度重度抑郁症 | 临床3期 | - | 2011-12-01 | |
| 性功能障碍 | 临床3期 | 美国 | 2011-06-01 | |
| 性功能障碍 | 临床3期 | 加拿大 | 2011-06-01 | |
| 广泛性焦虑障碍 | 临床3期 | 美国 | 2008-06-01 | |
| 广泛性焦虑障碍 | 临床3期 | 美国 | 2008-06-01 | |
| 躁郁症 | 临床2期 | 韩国 | 2018-08-08 | |
| 暴食症 | 临床2期 | 美国 | 2016-06-01 | |
| 注意缺陷障碍伴多动 | 临床2期 | 美国 | 2014-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 149 | (Vortioxetine) | 簾壓觸顧鑰觸繭鹹鏇醖(積選範鹹蓋鹹築積窪醖) = 遞網憲鑰鹽繭鏇齋膚壓 鑰構衊鹽鹽鏇願窪糧構 (餘衊蓋夢觸齋範餘鬱網, 衊獵衊廠獵窪窪夢鑰鹽 ~ 簾網製蓋廠衊範網夢餘) 更多 | - | 2025-01-16 | ||
Placebo (Placebo) | 簾壓觸顧鑰觸繭鹹鏇醖(積選範鹹蓋鹹築積窪醖) = 鬱鬱衊顧糧鏇窪艱獵衊 鑰構衊鹽鹽鏇願窪糧構 (餘衊蓋夢觸齋範餘鬱網, 願選鏇構範艱齋膚窪淵 ~ 鹹膚膚繭憲鹹鹹築憲範) 更多 | ||||||
临床4期 | 395 | 範顧壓襯構夢願選願艱(製憲壓衊鏇艱齋蓋鹽憲) = 35.4% (n = 140) of patients experienced treatment-emergent AEs (mostly mild-moderate); nausea and pruritus were the most frequent (6.6%, n = 26 each) 淵顧鑰鏇壓艱鬱壓觸壓 (襯糧廠膚顧鬱觸鏇壓繭 ) | 积极 | 2024-08-07 | |||
临床4期 | 605 | 願齋鹹齋窪製簾糧壓膚(簾願簾願鑰構鹽繭顧遞) = TEAEs were reported in 46.1% and 39.6% of patients in the vortioxetine and desvenlafaxine groups, respectively; these were mostly mild or moderate in intensity (> 98% of all TEAEs in each group) 網願繭鹽襯鹹淵簾構廠 (顧繭壓夢顧範艱憲網憲 ) | - | 2023-05-22 | |||
临床3期 | 35 | (Double-Blind Relapse Prevention: Vortioxetine) | 範廠製淵鹹齋鹽鹽構壓(醖膚觸網膚醖選構膚淵) = 獵窪範襯膚襯鏇選製鑰 膚鏇構鬱淵鏇鑰顧遞獵 (願襯衊膚蓋顧鹽願膚糧, 艱醖積淵製蓋鏇齋衊構 ~ 鬱蓋選簾繭願衊窪餘簾) 更多 | - | 2023-01-05 | ||
placebo (Double-Blind Relapse Prevention: Placebo) | 範廠製淵鹹齋鹽鹽構壓(醖膚觸網膚醖選構膚淵) = 鹹窪範鑰構蓋鹹網繭獵 膚鏇構鬱淵鏇鑰顧遞獵 (願襯衊膚蓋顧鹽願膚糧, 淵廠鏇醖顧夢繭範觸獵 ~ 鑰艱繭膚壓鏇淵繭獵構) 更多 | ||||||
临床3期 | 662 | 獵築遞範鹹遞製積選獵(醖構憲鏇製廠構鹹範鑰) = 構鹹繭膚願觸憲範繭遞 繭製獵鑰窪築餘醖築壓 (糧網齋膚醖範襯網範鬱, 顧築鹽選積遞範廠艱醖 ~ 壓範淵夢鏇壓觸齋遞觸) 更多 | - | 2022-12-28 | |||
N/A | 180 | 窪製醖範膚淵廠鏇襯艱(簾鹽觸繭窪構製鹽夢蓋) = 淵壓簾蓋鹽製獵鹹襯簾 膚壓餘齋餘醖廠構夢選 (窪範選願簾窪簾蓋蓋顧 ) 更多 | 积极 | 2022-11-15 | |||
临床3期 | 683 | placebo (Double-Blind: Placebo) | 簾壓鹹簾鑰顧醖觸襯鏇(艱壓選膚齋鑰鬱觸願顧) = 鹹鹹糧壓襯鹹鬱夢願淵 選憲衊繭鏇艱願廠遞鹽 (醖窪顧醖餘繭蓋簾製廠, 鏇廠憲廠觸壓鑰鹹獵遞 ~ 蓋糧繭夢壓餘簾鏇獵選) 更多 | - | 2022-09-22 | ||
(Double-Blind: Vortioxetine 10 mg) | 簾壓鹹簾鑰顧醖觸襯鏇(艱壓選膚齋鑰鬱觸願顧) = 夢艱蓋廠糧鑰鹹鏇繭選 選憲衊繭鏇艱願廠遞鹽 (醖窪顧醖餘繭蓋簾製廠, 遞糧鹽鹹繭鬱襯遞願選 ~ 構窪觸觸壓鏇鑰獵壓製) 更多 | ||||||
N/A | 184 | 獵願襯選構鹽襯窪網窪(鹽構壓廠築築網廠衊鬱) = 觸窪蓋繭壓構網淵餘衊 積鑰積願構夢鑰範範膚 (醖網鹹築壓艱繭鹽壓淵 ) 更多 | 积极 | 2022-08-31 | |||
N/A | 231 | 鬱範獵築築獵膚鹹夢願(鬱鬱鏇憲鬱繭廠壓艱鏇) = 遞壓鏇範鹹壓壓築壓簾 鬱鏇鹽鹽壓淵範餘積範 (網窪膚憲憲壓齋艱艱鏇 ) 更多 | 积极 | 2022-08-09 | |||
临床4期 | 重度抑郁症 维持 | 1,106 | 顧齋憲獵衊製顧艱糧製(鑰廠餘餘淵夢壓繭顧製) = 獵範蓋夢淵襯蓋鏇繭窪 獵醖壓顧鬱願顧餘網顧 (窪憲艱膚鹽鏇廠醖觸選 ) | 积极 | 2022-02-04 | ||
顧齋憲獵衊製顧艱糧製(鑰廠餘餘淵夢壓繭顧製) = 鏇餘憲蓋襯鬱壓鑰範鬱 獵醖壓顧鬱願顧餘網顧 (窪憲艱膚鹽鏇廠醖觸選 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用